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Textilinin-1, an alternative anti-bleeding agent to aprotinin:
Importance of plasmin inhibition in controlling blood loss
The use of aprotinin for cardiac surgery has been associated
with an increased incidence of myocardial infarction, vein graft
occlusion and anaphylactic shock (Wuthrich et al, 1992;
Cohen et al, 1999; Beierlein et al, 2005; Engles, 2005; Karkouti
& Beattie, 2006; Mangano et al, 2006; Sodha et al, 2006). In a
large-scale observational study, Mangano et al (2006) found
that the use of aprotinin was associated with an increased risk
of adverse renal and non-renal events in aprotinin-treated
groups of cardiac surgery patients when compared with
an untreated group. A multicentre study from the Blood
Conservation using Antifibrinolytics in a Randomized Trial
(BART) revealed a strong and consistent negative mortality
trend associated with the use of aprotinin compared to the
lysine analogues, precluding its use in high risk cardiac surgery
(Fergusson et al, 2008).
The serine protease inhibitor, textilinin-1, from the venom
of the Australian eastern brown snake, Pseudonaja textilis is
related in sequence to aprotinin and exhibits a three-dimen-
sional structure typical of Kunitz/BPTI-type inhibitors (Masci
et al, 2000; Filippovich et al, 2002; Millers et al, 2006). In
preliminary studies, textilinin-1 was found to strongly inhibit
plasmin and trypsin (Flight et al, 2005) and to reduce blood
loss in an animal model (Masci et al, 2000). We describe here
an expanded kinetic study of the inhibition of serine proteases
involved in haemostasis by textilinin-1 and aprotinin. We also
report a comparison of the effects of these two inhibitors on
the clotting of plasma and whole blood, on lysis of whole blood
clots, and on blood loss in an animal model.
Materials and methods
Enzyme reaction rates were obtained by continuous monitor-
ing of p-nitroaniline production at 405 nm from specific
peptide substrates. Inhibitor dissociation constants (Ki)
were determined by non-linear regression analysis of pro-
gress curves using the two-step model and equations of
Morrison and Walsh (1988), and commercial software
(sigmaplot 8; Systat Software Inc., CA, USA). Activated
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Aprotinin has been used widely in surgery as an anti-bleeding agent but is
associated with a number of side effects. We report that textilinin-1, a serine
protease inhibitor from Pseudonaja textilis venom with sequence relatedness
to aprotinin, is a potent but reversible plasmin inhibitor and has a narrower
range of protease inhibition compared to aprotinin. Like aprotinin,
textilinin-1 at 5 lmol/l gave almost complete inhibition of tissue
plasminogen activator-induced fibrinolysis of whole blood clots. The
activated partial thromboplastin time for plasma was markedly increased
by aprotinin but unaffected by textilinin-1. In a mouse tail-vein bleeding
model, intravenous textilinin-1 and aprotinin caused similar decreases in
blood loss but time to haemostasis in the textilinin-treated animals was
significantly shorter than in aprotinin-treated mice. Based on these data,
textilinin-1 merits further investigation as a therapeutic alternative to
aprotinin.
Keywords: textilinin-1, aprotinin, serine protease inhibitor, anti-bleeding,
anti-fibrinolytic.
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partial thromboplastin time (aPTT) and prothrombin time
(PT) were measured as described (Austen & Rhymes, 1975).
Thromboelastography of citrated whole blood was performed
using a Thrombelastograph (TEG; Haemoscope Corpora-
tion Pty Ltd, Niles, IL, USA). The reaction time (R) is the time
from initiation to the formation of the first detectable clot. The
percentages of clot lysis at 60 and 180 min after maximum
amplitude (MA) are the LY60 and LY180 values.
The mouse tail-vein bleeding model was adapted from that
of Tanabe et al (1999). Textilinin-1 or aprotinin was injected
into the tail veins of adult B57/BL mice (20–30 g) at a
concentration of 50 lmol/l to give an expected circulating
concentration of approximately 5 lmol/l (assuming a plasma
volume of 1 ml and exclusion from red cells). The mice were
anaesthetized (isofluorane, 2Æ5%, 1Æ5 l/min) and blood loss
from the excised tail was then adsorbed onto a filter paper chad
and haemoglobin measured by the method of Shaw et al
(1972). Ethical approval was obtained from the Animal Care
Committee of the Queensland Institute of Medical Research
and the University of Queensland Animals Ethics Committee
and protocols were compliant with National Health and
Medical Research Council Animal Experimental Ethics Com-
mittee guidelines.
Statistical analysis was performed with the programs sas,
version for Windows 9Æ1 (SAS Institute, Cary, NC, USA) and
stata/se 9Æ2 for Windows (Stata Corp LP, College Station,
TX, USA). Analysis of variance (anova) was used to compare
average blood loss in the treatment groups. Average blood loss
was log-transformed prior to analysis to remove positive skew
and Tukey’s studentized range test for multiple comparisons
was used to compare treatment groups. In all cases significance
was defined as P < 0Æ05.
Results
Inhibition of serine proteases involved in coagulation
and fibrinolysis
Aprotinin proved to be a more potent inhibitor than
textilinin-1 of several different serine proteases, as shown
quantitatively by the Ki ratios (Table I). Based on these
results, at therapeutic doses used for aprotinin (2 and
5 lmol/l) both textilinin-1 and aprotinin would be expected
to produce complete or almost complete inhibition of
plasmin. Aprotinin would also cause extensive inhibition
of plasma kallikrein, whereas textilinin-1 would have little or
no effect. For activated protein C (APC), neutrophil elastase
and tissue kallikrein, aprotinin would be expected from the
Ki values to cause significant inhibition at therapeutic doses,
whereas textilinin-1 would have little or no effect. Aprotinin
is also a better inhibitor of tissue plasminogen activator
(t-PA) and urokinase, but the Ki values for these enzymes
are in excess of the therapeutic dose. No significant
inhibition by either inhibitor was detected for a and b
factor XIIa, VIIa, Xa, or thrombin. Table I also includes
previously published Ki values for human plasmin and
bovine trypsin.
Effects of textilinin-1 and aprotinin on the extrinsic
coagulation pathway
Effectors of the extrinsic coagulation pathway can be identified
using the prothrombin time (PT) assay (Colman, 2006).
Consistent with the failure to observe inhibition of factor VIIa,
factor Xa, and thrombin, concentrations of textilinin-1 and
aprotinin up to 12 lmol/l had no effect on PT (measured PT at
0 and 12 lmol/l was 12 ± 2 s). Thus, neither textilinin-1 nor
aprotinin appeared to have any effect on the extrinsic pathway
of blood coagulation at concentrations up to and exceeding
those found in plasma during the high-dose Hammersmith
regimen in cardiac surgery (Royston et al, 1987).
Effect of inhibitors on the intrinsic coagulation pathway
Plasma kallikrein is a component of the intrinsic pathway and
its inhibition would be expected to result in the inhibition of
coagulation by this pathway. The aPTT measures the clotting
time resulting from the activation of factor XII by plasma
kallikrein formed from prekallikrein by the action of kinin.
The aPTT was prolonged by aprotinin in a dose-dependent
manner whereas textilinin-1 had no significant effect (Fig 1A).
These differential effects were reinforced by the thromboelas-
tograph reaction time for aprotinin, which was significantly
larger than the control, while that for textilinin-1 was not
(Fig 1B and C). Thus, clot formation in whole blood by the







t-PA >500 · 103 (30 ± 5) · 103 >17
Urokinase >100 · 103 (30 ± 8) · 103
8 · 103*
>3
APC >100 · 103 (5 ± 1) · 103
1Æ35 · 103
>20
Elastase >100 · 103 (2Æ6 ± 0Æ5) · 103
3Æ5 · 103*
>38
Plasma kallikrein 4830 ± 610 16Æ4 ± 0Æ7– 295
Tissue kallikrein (12Æ9 ± 1Æ1) · 103 1Æ3 ± 0Æ1
1Æ0*
9Æ9 · 103
Plasmin 3Æ5 ± 0Æ3 0Æ053 ± 0Æ004– 66
Trypsin 0Æ76 ± 0Æ02 6Æ0 · 10)5* 1Æ3 · 104
*Engles, 2005.
Taby et al, 1990.
Masci et al, 2000.
§Ki (textilinin-1)/Ki (aprotinin).
–Time dependent inhibition. Values quoted are for Ki
* (Morrison &
Walsh, 1988).
Results are means ± standard deviation (n ‡ 5).
t-PA, tissue plasminogen activator; APC, activated protein C.
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intrinsic pathway was significantly (P < 0Æ001) retarded by
aprotinin, but unaffected by textilinin-1.
The effects of textilinin-1 and aprotinin on fibrinolysis
of whole blood clots
Based on our in vitro kinetic measurements (Table I), it was
predicted that both aprotinin and textilinin-1 would inhibit
t-PA-induced fibrinolysis. The effect of the inhibitors on
fibrinolysis of clots formed in citrated whole blood by
activation of the intrinsic pathway was assessed by thrombo-
elastography. t-PA was added to give a high rate of fibrinolysis
in test samples. Overlaid TEG traces are shown in Fig 1B.
Addition of calcium and kaolin resulted in the formation of a
strong clot with minimal fibrinolysis during the test period
(trace d). Addition of t-PA as well resulted in rapid fibrinolysis,
preventing formation of a strong clot (trace a). Addition of
either textilinin-1 or aprotinin as well as t-PA resulted in a
dose-dependent inhibition of fibrinolysis for 2 and 5 lmol/l
inhibitor concentrations. At inhibitor concentrations of
5 lmol/l (as for aprotinin in the high dose Hammersmith
regime, Royston et al, 1987), both inhibitors caused complete
or almost complete inhibition of fibrinolysis (traces c Fig 1B).
At 2 lmol/l inhibitor concentration (as in the low dose
Hammersmith regime, Royston et al, 1988), aprotinin yielded
2Æ6% and 4Æ0% clot lysis at 60 and 180 min respectively
compared with 11% and 80% for textilinin-1 treated clots for
the corresponding time points (traces b in Fig 1B, and Fig 1C).
These results for clot lysis suggest that textilinin-1 would be
effective as an anti-bleeding agent in vivo and are consistent
with the ‘‘66-fold’’ tighter binding of aprotinin to plasmin
observed in Ki values listed in Table I.
Effects of textilinin-1 and aprotinin on blood loss in an
animal model
In a mouse tail vein bleeding model both textilinin-1 and
aprotinin had a marked effect on blood loss compared to
(A) (B)
(C) (D)
Fig 1. Effect of aprotinin (hatched bars) and textilinin-1 (cross-hatched bars) compared with controls (open bars) on clotting of citrated plasma and
whole blood by re-calcification. (A) Activated partial thromboplastin time (aPTT) of pooled human plasma in the presence of inhibitors (0Æ4–
12 lmol/l, n = 3). (B) Representative thromboelastograms illustrating the formation and lysis of whole blood clots in the presence of calcium, kaolin,
t-PA (92 IU/ml), and either textilinin-1 (upper panel) or aprotinin (lower panel) at concentrations of 0 (trace a), 2 (trace b) and 5 lmol/l (trace c).
Trace (d) shows clotting and fibrinolysis without the addition of t-PA or inhibitor. (C) TEG parameters: reaction time R (time from initiation to
formation of the first detectable clot) in the absence of t-PA (n = 6); LY60 and LY180 (% clot lysis at 60 and 180 min after maximum amplitude
respectively) in the presence of inhibitors (2 lmol/l) and t-PA (n = 12). (D) Effect of saline (n = 19), aprotinin (n = 15) and textilinin-1 (n = 26) on
blood loss in a mouse tail vein bleeding model. Inhibitors were injected into the tail vein, to give plasma inhibitor concentration of approximately
5 lmol/l. Average blood loss was log-transformed prior to analysis to remove positive skew. Dunnett’s t-test for multiple comparisons was used to
compare experimental treatment groups with the control (saline injection) group and follow up time points with the baseline result at time = 0 min.
Results are shown as mean ± SE, and significant differences from controls by asterisks (* P < 0Æ05, ** P < 0Æ025, *** P < 0Æ001).
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control (Fig 1D). The average total blood loss was reduced by
37% (P = 0Æ019) in textilinin-1 treated animals and by 33%
(P = 0Æ018) in animals injected with aprotinin, compared with
saline. After 3 min, there was a significant reduction in blood
loss in the textilinin-1 treated animals compared to the saline
group (P = 0Æ022) while in aprotinin-treated animals, a
significant effect was only observed after 4 min (P = 0Æ026),
suggesting a longer time to haemostasis in the aprotinin-
treated animals. Focussing on the 3–5 min time period after
injury, the blood loss of textilinin-1 treated animals
(29Æ5 ± 33Æ0 ll) was significantly less than the blood loss from
aprotinin-treated animals (49Æ7 ± 22Æ8 ll; P = 0Æ01). These
results are consistent with significant inhibition of coagulation
by aprotinin but not by textilinin-1 (see Fig 1A, B).
Discussion
The present study has shown that textilinin-1 is an effective
inhibitor of plasmin-catalysed fibrinolysis of whole blood clots
and reduces blood loss in an animal model, suggesting that it
should be an effective anti-bleeding agent. Textilinin-1 was
shown to be a very weak inhibitor of plasma kallikrein and,
consistent with this observation, had a negligible effect on the
aPTT of recalcified citrated plasma (Fig 1A). In agreement
with previous results, aprotinin was found to be a potent
inhibitor of plasmin and of fibrinolysis (Sodha et al, 2006). In
contrast to textilinin-1, it is also an inhibitor of plasma and
tissue kallikreins and of the intrinsic blood coagulation
pathway, as shown by its effect on the aPTT (Fig 1A) and
the R time (Fig 1C).
Textilinin-1, aprotinin and DX-88, a kallikrein inhibitor
produced by Dyax Corporation, (Tanaka et al, 2004; http://
www.dyax.com/clinical/cardiacsurg.html) are all Kunitz-type
serine protease inhibitors capable of controlling blood loss and
provide useful mechanistic comparisons. Textilinin-1 inhibits
plasmin strongly and plasma kallikrein to a minimal extent.
DX-88 inhibits plasma kallikrein strongly but not plasmin,
while aprotinin is a potent inhibitor of both plasmin and
plasma kallikrein. Aprotinin has been used successfully to
reduce post-operative bleeding after cardiac surgery. DX-88,
which is reported to have no anti-fibrinolytic activity (consis-
tent with its inability to inhibit plasmin), has also been
reported to reduce blood loss in cardiac surgery (Tanaka et al,
2004; http://www.dyax.com/clinical/cardiacsurg.html). Textili-
nin-1 was found to reduce blood loss when injected intrave-
nously in an animal model (Fig 1D). In the present study,
intravenous textilinin-1 and aprotinin both significantly
reduced blood loss but textilinin-1 treated mice attained
haemostasis more rapidly than aprotinin-treated mice.
The lysine analogs e-aminocaproic acid and tranexamic acid
have also been found to reduce blood loss in cardiac surgery
(Hekmat et al, 2004; Levy et al, 2005). These compounds bind
to lysine binding sites on plasminogen, in competition with
fibrin (Colman, 2006). As t-PA activates plasminogen much
more rapidly when it is bound to fibrin than when it is free, the
effect of the lysine analogs is to decrease the rate of formation
of plasmin and hence to inhibit fibrinolysis. Whether the
ability of textilinin-1 and aprotinin to inhibit plasmin directly
makes them superior to the lysine analogs for certain
applications remains to be investigated. The current literature
indicates that drugs which function by reducing plasmin
activity (textilinin-1, lysine analogs and aprotinin) and drugs
which inhibit plasma kallikrein (DX-88 and aprotinin), reduce
blood loss. The relative importance of these two mechanisms
in different surgical situations remains to be established.
Despite the 45% identity in amino acid sequence and
identical positioning of the disulfide bonds, textilinin-1 and
aprotinin have different specificity as protease inhibitors. The
observed inhibition of various trypsin-like enzymes by apro-
tinin may enhance its effectiveness in cardiac surgery but may
be responsible for adverse side effects. Inhibition of APC by
aprotinin would enhance thrombin production and prolong
coagulation events, which could cause clot extension (forma-
tion of additional clot by the action of fibrin bound thrombin),
as suggested by Espana et al (2005). The present study has
confirmed that aprotinin (but not textilinin-1) is a potent
inhibitor of tissue kallikrein (urinary kallikrein). Consistent
with the anti-bleeding results, the pattern of inhibition by
aprotinin should lead to slower but more stable clot formation,
whereas textilinin-1 would be expected to allow faster clot
formation while showing potent but reversible anti-fibrinolytic
properties.
At therapeutic doses, aprotinin is concentrated in the kidney
where it selectively binds to the brush border of the proximal
tubules, then enters the cytoplasm inhibiting protease secretion
(Mangano et al, 2006). Inhibition of urinary kallikrein and/or
other serine proteases in the kidney may account for the renal
dysfunction reported as an adverse effect of aprotinin usage in
cardiac surgery (Karkouti & Beattie, 2006; Mangano et al,
2006).
We have demonstrated here the efficacy of intravenous
textilinin-1 in reducing surgical blood loss in an animal model.
These results together with the in vitro whole blood coagula-
tion and fibrinolysis, and the enzyme specificity data suggest
that textilinin-1 has the potential to be a safer anti-bleeding
agent than aprotinin. Furthermore, the availability of an
immunologically distinct (Filippovich et al, 2002) alternative
to aprotinin is desirable, given the risks inherent in repeated
use of aprotinin. Because of the multiple roles of plasmin
(Syrovets & Simmet, 2004), the availability of a selective
plasmin inhibitor opens up further therapeutic possibilities.
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